651 related articles for article (PubMed ID: 11867112)
1. Use of proteomic patterns in serum to identify ovarian cancer.
Petricoin EF; Ardekani AM; Hitt BA; Levine PJ; Fusaro VA; Steinberg SM; Mills GB; Simone C; Fishman DA; Kohn EC; Liotta LA
Lancet; 2002 Feb; 359(9306):572-7. PubMed ID: 11867112
[TBL] [Abstract][Full Text] [Related]
2. Progress and challenges in screening for early detection of ovarian cancer.
Jacobs IJ; Menon U
Mol Cell Proteomics; 2004 Apr; 3(4):355-66. PubMed ID: 14764655
[TBL] [Abstract][Full Text] [Related]
3. Use of serological proteomic methods to find biomarkers associated with breast cancer.
Rui Z; Jian-Guo J; Yuan-Peng T; Hai P; Bing-Gen R
Proteomics; 2003 Apr; 3(4):433-9. PubMed ID: 12687611
[TBL] [Abstract][Full Text] [Related]
4. Clinical potential of proteomics in the diagnosis of ovarian cancer.
Ardekani AM; Liotta LA; Petricoin EF
Expert Rev Mol Diagn; 2002 Jul; 2(4):312-20. PubMed ID: 12138495
[TBL] [Abstract][Full Text] [Related]
5. Tree analysis of mass spectral urine profiles discriminates transitional cell carcinoma of the bladder from noncancer patient.
Zhang YF; Wu DL; Guan M; Liu WW; Wu Z; Chen YM; Zhang WZ; Lu Y
Clin Biochem; 2004 Sep; 37(9):772-9. PubMed ID: 15329315
[TBL] [Abstract][Full Text] [Related]
6. [Preliminary study on proteomic patterns in hepatic tissue to identify HBV related hepatocellular carcinoma].
Long YZ; Fan XG; Li N; Huang YK
Zhonghua Gan Zang Bing Za Zhi; 2004 Apr; 12(4):231-3. PubMed ID: 15099477
[TBL] [Abstract][Full Text] [Related]
7. Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology.
Mok SC; Chao J; Skates S; Wong K; Yiu GK; Muto MG; Berkowitz RS; Cramer DW
J Natl Cancer Inst; 2001 Oct; 93(19):1458-64. PubMed ID: 11584061
[TBL] [Abstract][Full Text] [Related]
8. High-resolution serum proteomic features for ovarian cancer detection.
Conrads TP; Fusaro VA; Ross S; Johann D; Rajapakse V; Hitt BA; Steinberg SM; Kohn EC; Fishman DA; Whitely G; Barrett JC; Liotta LA; Petricoin EF; Veenstra TD
Endocr Relat Cancer; 2004 Jun; 11(2):163-78. PubMed ID: 15163296
[TBL] [Abstract][Full Text] [Related]
9. Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women.
Skates SJ; Menon U; MacDonald N; Rosenthal AN; Oram DH; Knapp RC; Jacobs IJ
J Clin Oncol; 2003 May; 21(10 Suppl):206s-210s. PubMed ID: 12743136
[TBL] [Abstract][Full Text] [Related]
10. The use of plasma surface-enhanced laser desorption/ionization time-of-flight mass spectrometry proteomic patterns for detection of head and neck squamous cell cancers.
Soltys SG; Le QT; Shi G; Tibshirani R; Giaccia AJ; Koong AC
Clin Cancer Res; 2004 Jul; 10(14):4806-12. PubMed ID: 15269156
[TBL] [Abstract][Full Text] [Related]
11. New tumor markers: CA125 and beyond.
Bast RC; Badgwell D; Lu Z; Marquez R; Rosen D; Liu J; Baggerly KA; Atkinson EN; Skates S; Zhang Z; Lokshin A; Menon U; Jacobs I; Lu K
Int J Gynecol Cancer; 2005; 15 Suppl 3():274-81. PubMed ID: 16343244
[TBL] [Abstract][Full Text] [Related]
12. Proteomic studies of early-stage and advanced ovarian cancer patients.
Wang J; Zhang X; Ge X; Guo H; Xiong G; Zhu Y
Gynecol Oncol; 2008 Oct; 111(1):111-9. PubMed ID: 18703221
[TBL] [Abstract][Full Text] [Related]
13. Assessment of symptomatic women for early diagnosis of ovarian cancer: results from the prospective DOvE pilot project.
Gilbert L; Basso O; Sampalis J; Karp I; Martins C; Feng J; Piedimonte S; Quintal L; Ramanakumar AV; Takefman J; Grigorie MS; Artho G; Krishnamurthy S;
Lancet Oncol; 2012 Mar; 13(3):285-91. PubMed ID: 22257524
[TBL] [Abstract][Full Text] [Related]
14. Plasma proteomic pattern as biomarkers for ovarian cancer.
Lin YW; Lin CY; Lai HC; Chiou JY; Chang CC; Yu MH; Chu TY
Int J Gynecol Cancer; 2006; 16 Suppl 1():139-46. PubMed ID: 16515582
[TBL] [Abstract][Full Text] [Related]
15. Status of tumor markers in ovarian cancer screening.
Bast RC
J Clin Oncol; 2003 May; 21(10 Suppl):200s-205s. PubMed ID: 12743135
[TBL] [Abstract][Full Text] [Related]
16. Proteomic approaches to tumor marker discovery.
Rai AJ; Zhang Z; Rosenzweig J; Shih IeM; Pham T; Fung ET; Sokoll LJ; Chan DW
Arch Pathol Lab Med; 2002 Dec; 126(12):1518-26. PubMed ID: 12456215
[TBL] [Abstract][Full Text] [Related]
17. Haptoglobin-alpha subunit as potential serum biomarker in ovarian cancer: identification and characterization using proteomic profiling and mass spectrometry.
Ye B; Cramer DW; Skates SJ; Gygi SP; Pratomo V; Fu L; Horick NK; Licklider LJ; Schorge JO; Berkowitz RS; Mok SC
Clin Cancer Res; 2003 Aug; 9(8):2904-11. PubMed ID: 12912935
[TBL] [Abstract][Full Text] [Related]
18. Proteomic analysis of serum of women with elevated Ca-125 to differentiate malignant from benign ovarian tumors.
Li L; Xu Y; Yu CX
Asian Pac J Cancer Prev; 2012; 13(7):3265-70. PubMed ID: 22994745
[TBL] [Abstract][Full Text] [Related]
19. [Identification of new ovarian cancer biomarkers with proteomic analyses--the diagnostic tool of the future?].
Petri AL; Høgdall E; Engelholm SA; Christensen IJ; Kjaer SK; Høgdall CK
Ugeskr Laeger; 2007 Aug; 169(33):2614-9. PubMed ID: 17725906
[TBL] [Abstract][Full Text] [Related]
20. New technologies for the identification of markers for early detection of ovarian cancer.
Bandera CA; Ye B; Mok SC
Curr Opin Obstet Gynecol; 2003 Feb; 15(1):51-5. PubMed ID: 12544502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
